Oncology and Autoimmune Diseases
B1963Indication——Advanced malignant solid tumors
(1) Drugabbility evaluation has demonstrated that B1963 is comparable to Utomilumab of Pfizer—an antibody with the same target, under clinical trial—in terms of promoting T cell expansion and cytokine expression;
(2) Has higher affinity to CD137 on the surface of memory CD4+ T cells; when used in combination with PD-L1, significantly superior to Tecentrip in terms of the efficacy of stimulating memory CD4+ T cells;
(3) Expected to have enhanced therapeutic effects on B-cell lymphomas and melanomas, among other cancers, when combined with other medications.
Next important events and time points
It is anticipated that preclinical pharmacodynamics, pharmacokinetics and safety evaluation studies will be initiated in the second quarter of 2021, and an IND application will be filed in the second quarter of 2022.